Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
Status:
Completed
Trial end date:
2019-06-11
Target enrollment:
Participant gender:
Summary
Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify
the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel
(intranasal scopolamine gel) for the prevention and treatment of nausea associated with
motion sickness.